You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
东阳光(600673.SH):阳之康医药获苯甲酸阿格列汀片药品注册证书
格隆汇 12-23 16:56

格隆汇12月23日丨东阳光(600673.SH)公布,公司控股子公司东莞市阳之康医药有限责任公司(以下简称“阳之康医药”)于近日收到国家药监局核准签发的苯甲酸阿格列汀片《药品注册证书》。

阿格列汀(C18H21N5O2)属于二肽基肽酶4抑制剂(“DPP-4抑制剂”)类药物,用于治疗成人2型糖尿病。该类药物能够抑制胰高血糖素样肽-1(“GLP-1”)和葡萄糖依赖性促胰岛素分泌多肽(“GIP”)的灭活,提高内源性GLP-1和GIP的水平,促进胰岛β细胞释放胰岛素,同时抑制胰岛α细胞分泌胰高血糖素,从而提高胰岛素水平,降低血糖,且不易诱发低血糖和体重增加。

阿格列汀是《国家基本医疗保险、工伤保险和生育保险药品目录》2019年版中乙类品种。根据艾美仕中国数据显示,2019年国内公立医疗机构DPP-4抑制剂类药物销售金额约为2.59亿美元,较2018增长约52.61%,是糖尿病治疗领域的主要用药品种之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account